Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA ‐4359 for Use in First‐In‐Human Trials
CPT: Pharmacometrics & Systems Pharmacology · 2026-02 · 15 (2)
DOI: 10.1002/psp4.70188 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 28.01.2026. Verfasst von Stephen A Greene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, Neoplasms, RNA, Messenger. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The investigational antigen‐specific immunotherapy mRNA‐4359 is a lipid nanoparticle–encapsulated mRNA‐based immunotherapy that encodes for the immunogenic indoleamine 2,3‐dioxygenase (IDO) and programmed death‐ligand 1 (PD‐L1) antigens. An ongoing first‐in‐human (FIH) phase 1/2 clinical trial (NCT05533697) will evaluate the safety and antitumor activity of mRNA‐4359 when administered alone and in combination with the anti–programmed death‐1 agent pembrolizumab in participants with advanced solid tumors. The current analysis applied a novel immunostimulatory/immunodynamic (IS/ID) modeling approach to determine a plausible starting dose of mRNA‐4359 for the FIH trial. The model used for the FIH dose prediction was calibrated to previously published clinical trial data obtained for an immunomodulatory peptide‐based vaccine activating IDO‐ and PD‐L1–specific T cells in patients with metastatic melanoma. The analysis found that a 180 μg dose of mRNA‐4359 would possibly elicit a T‐cell response similar to a 200 μg dose of the peptide‐based vaccine with a range of 45–360 μg, assuming a potential 4‐fold higher to 2‐fold lower efficiency (the ability to elicit IFN‐γ secreting T cells, indicative of cytotoxic potential). Model simulations further predicted that a 15‐cycle every 3 weeks regimen of mRNA‐4359 could be expected to provide longer responses than other feasible simulated regimens. Finally, the IS/ID modeling analysis determined that a 100 μg dose of mRNA‐4359 would be the most appropriate starting dose for FIH trials. The described approach represents a unique application of IS/ID modeling to determine a therapeutically relevant FIH starting dose in the absence of supporting preclinical animal data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moderna, Inc., Cambridge, Massachusetts, USA.
- Vantage Research, Inc., Lewes, Delaware, USA.
ORCID-Profile: Stephen A Greene, Bhairav Paleja, Min Liang
Zitieren
APA
Greene, S. A., Channavazzala, M., Paleja, B., Sandhu, H. S., Kumar, R., Attarwala, H., Van, L., & Liang, M. (2026). Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA ‐4359 for Use in First‐In‐Human Trials. CPT: Pharmacometrics & Systems Pharmacology, 15(2). https://doi.org/10.1002/psp4.70188
Vancouver
Greene SA, Channavazzala M, Paleja B, Sandhu HS, Kumar R, Attarwala H, et al. Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA ‐4359 for Use in First‐In‐Human Trials. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(2). doi:10.1002/psp4.70188
BibTeX
@article{Greene2026,
author = {Greene, Stephen A and Channavazzala, Madhav and Paleja, Bhairav and Sandhu, Harshbir Singh and Kumar, Rukmini and Attarwala, Husain and Van, Linh and Liang, Min},
title = {Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA ‐4359 for Use in First‐In‐Human Trials},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {2},
doi = {10.1002/psp4.70188}
}
EUVIMED